UCB Pharma (VOGALENE And VOGALIB) Overview
- Status
- Acquired/Merged
- Latest Deal Type
- Asset Purch.
- Financing Rounds
- 1
UCB Pharma (VOGALENE And VOGALIB) General Information
Description
Two medicinal products. The portfolio comprises of development, manufacturing, marketing and sale of Vogalib(R) and Vogalene(R) medicines. They are approved for use in the symptomatic treatment of nausea and vomiting. The injectible is approved for the prevention of nausea and vomiting in patients under chemotherapy.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Primary Office
- France
UCB Pharma (VOGALENE And VOGALIB) Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore UCB Pharma (VOGALENE And VOGALIB)‘s full profile, request access.
Request a free trialUCB Pharma (VOGALENE And VOGALIB) Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore UCB Pharma (VOGALENE And VOGALIB)‘s full profile, request access.
Request a free trial